(Q36394371)

13 August 2017

1 reference

title

The metabolic syndrome, hyperlipidemia, and insulin resistance (English)

1 reference

13 August 2017

1 reference

1 reference

1 reference

Vivian A Fonseca

1

1 reference

13 August 2017

publication date

1 January 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

7

1 reference

13 August 2017

issue

2-3

1 reference

13 August 2017

page(s)

61-72

1 reference

The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

Metabolic syndrome in relationship to type 2 diabetes and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

Abdominal obesity is associated with increased risk of acute coronary events in men.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

What is the contribution of obesity to the metabolic syndrome?

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

Metabolic and vascular abnormalities in subjects at risk for type 2 diabetes: the early start of a dangerous situation

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

Insulin resistance and risk of congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

Metabolic syndrome-interdependence of the cardiovascular and metabolic pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

Potential cardiovascular benefits of insulin sensitizers

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

Central obesity as a major determinant of increased high-sensitivity C-reactive protein in metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

Minireview: Adiposity, Inflammation, and Atherogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

Adipose tissue as an endocrine organ

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

Association of hypoadiponectinemia with coronary artery disease in men

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

The metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Québec Cardiovascular Study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

Insulin resistance syndrome: options for treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

Lipids and endothelium-dependent vasodilation--a review

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

Dyslipidemic hypertension: distinctive features and cardiovascular risk in a prospective population-based study.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S).

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

Targeting vascular risk in patients with metabolic syndrome but without diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

Role of insulin secretagogues and insulin sensitizing agents in the prevention of cardiovascular disease in patients who have diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

Targeting the metabolic syndrome with exercise: evidence from the HERITAGE Family Study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

New therapeutic options for the metabolic syndrome: what's next?

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

Emerging aspects of pharmacotherapy for obesity and metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

High constitutive signaling of the ghrelin receptor--identification of a potent inverse agonist

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

Rimonabant: unique and promising

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980069-9

7 January 2021

10.1016/S1098-3597(05)80069-9

Identifiers

DOI

1 reference

13 August 2017

1 reference